Trial reportHaematologica2018
Mutational screening of newly diagnosed multiple myeloma patients by deep targeted sequencing.
Abstract readClinical Trial, Phase IILetterRandomized Controlled Trial
In one paragraph
Trial report in Haematologica, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Cereblon gene variants and clinical outcome in multiple myeloma patients treated with lenalidomide.Scientific reports · 2019Trial
- The Evolving Role of Genomic Technologies in Multiple Myeloma: Implications for Diagnosis, Risk Stratification and Resistance.Molecular diagnosis & therapy · 2026Review
- NGS-Based Molecular Karyotyping of Multiple Myeloma: Results from the GEM12 Clinical Trial.Cancers · 2022Article
- Article
- Review
- Article
- Review
- Multiple myeloma with central nervous system relapse.Haematologica · 2020Review
- Germline CDKN1B Loss-of-Function Variants Cause Pediatric Cushing's Disease With or Without an MEN4 Phenotype.The Journal of clinical endocrinology and metabolism · 2020Article
- CIC Mutation as a Molecular Mechanism of Acquired Resistance to Combined BRAF-MEK Inhibition in Extramedullary Multiple Myeloma with Central Nervous System Involvement.The oncologist · 2020Article
- RAS/RAF mutations in tumor samples and cell-free DNA from plasma and bone marrow aspirates in multiple myeloma patients.Journal of Cancer · 2020Article
- Comparison of Clinical Characteristics and Genetic Aberrations of Plasma Cell Disorders in Thailand Population.Technology in cancer research & treatmentObservational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors.
Yanira Ruiz-HerediaDepartment of Hematology, Hospital Universitario 12 de Octubre-Hematological Malignancies Clinical Research Unit H120-CNIO, Madrid, Spain.
Beatriz Sánchez-VegaDepartment of Hematology, Hospital Universitario 12 de Octubre-Hematological Malignancies Clinical Research Unit H120-CNIO, Madrid, Spain.
Esther OnechaDepartment of Hematology, Hospital Universitario 12 de Octubre-Hematological Malignancies Clinical Research Unit H120-CNIO, Madrid, Spain.
Santiago BarrioDepartment of Internal Medicine II, University Hospital Würzburg, Germany.
Rafael AlonsoDepartment of Hematology, Hospital Universitario 12 de Octubre, Madrid, Spain.
Jose Carlos Martínez-ÁvilaClinical Pharmacology Department, La Paz University Hospital, idiPAZ, UAM, Madrid, Spain.
Isabel CuencaDepartment of Hematology, Hospital Universitario 12 de Octubre-Hematological Malignancies Clinical Research Unit H120-CNIO, Madrid, Spain.
Xabier AgirreDepartment of Hematology, Fundación de Investigacion Médica Aplicada (FIMA), Pamplona, Spain.
Esteban BraggioDepartment of Hematology, Mayo Clinic, Phoenix/Scottsdale, AZ, USA.
Miguel-T HernándezDepartment of Hematology, Hospital Universitario de Canarias, Tenerife, Spain.
Rafael MartínezDepartment of Hematology, Hospital Clínico Universitario San Carlos, Madrid, Spain.
Laura RosiñolDepartment of Hematology, Hospital Clínic of Barcelona, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), University of Barcelona, Spain.
Norma GutierrezDepartment of Hematology, Hospital Universitario de Salamanca-Centro Investigación del Cáncer and Hospital Universitario-IBSAL, Salamanca, Spain.
Marisa Martin-RamosDepartment of Hematology, Hospital Clínic of Barcelona, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), University of Barcelona, Spain.
Enrique M OcioDepartment of Hematology, Hospital Universitario de Salamanca-Centro Investigación del Cáncer and Hospital Universitario-IBSAL, Salamanca, Spain.
María-Asunción EchevesteDepartment of Hematology, Hospital Universitario Donostia, San Sebastián, Spain.
Jaime Pérez de OteyzaDepartment of Hematology, Hospital Madrid Norte Sanchinarro, Madrid, Spain.
Albert OriolDepartment of Hematology, Hospital Universitario de Salamanca-Centro Investigación del Cáncer and Hospital Universitario-IBSAL, Salamanca, Spain.
Joan BargayDepartment of Hematology, Hospital Sont Llatzer, Palma de Mallorca, Spain.
Mercedes GironellaDepartment of Hematology, Hospital Universitario Vall de Hebrón de Barcelona, Spain.
Rosa AyalaDepartment of Hematology, Hospital Universitario 12 de Octubre-Hematological Malignancies Clinical Research Unit H120-CNIO, Madrid, Spain.
Joan BladéDepartment of Hematology, Hospital Clinic i Provincial, Institut d'Investigasions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
María-Victoria MateosDepartment of Hematology, Hospital Universitario de Salamanca-Centro Investigación del Cáncer and Hospital Universitario-IBSAL, Salamanca, Spain.
Klaus M KortumDepartment of Internal Medicine II, University Hospital Würzburg, Germany.
Keith StewartDepartment of Hematology, Mayo Clinic, Phoenix/Scottsdale, AZ, USA.
Ramón García-SanzDepartment of Hematology, Hospital Universitario de Salamanca-Centro Investigación del Cáncer and Hospital Universitario-IBSAL, Salamanca, Spain.
Jesús San MiguelDepartment of Hematology, Fundación de Investigacion Médica Aplicada (FIMA), Pamplona, Spain.
Juan José LahuertaDepartment of Hematology, Hospital Universitario 12 de Octubre, Madrid, Spain.
Joaquín Martinez-LopezDepartment of Hematology, Hospital Universitario 12 de Octubre-Hematological Malignancies Clinical Research Unit H120-CNIO, Madrid, Spain jmarti01@med.ucm.es.
Funding
Project 4: Targeting Resistance to T-Cell Directed Therapy in Multiple MyelomaP50CA186781 · NCI · MAYO CLINIC ARIZONA · PI Rafael Fonseca · 2015 to 2026
$25.5MNCI NIH HHS P50 CA186781
Abstract
PubMed holds no abstract for this paper.
Indexed as
Databases, Nucleic AcidAgedAged, 80 and overDisease-Free SurvivalDNA Mutational AnalysisFemaleHigh-Throughput Nucleotide SequencingHumansMaleMultiple MyelomaNeoplasm ProteinsSurvival RateNeoplasm Proteins
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.